C-terminal agrin fragment
peptideA proteolytic agrin fragment that marks myocardial necrosis and predicts post-infarction acute kidney injury through systemic inflammatory and ischemic stress pathways.
Pathway placement
Cascade stepMyocardial injury (shared endpoint)
Confidencemedium
RationaleProteolytic agrin fragment released during myocardial injury; predicts acute kidney injury post-AMI.
Also acts inSystemic / off-pathway
Druggability
Not assessed (no mapped human gene target).
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Plasma (EDTA; peptidase-labile — chilled + protease inhibitor)
Collection tube
K2-EDTA, chilled plastic (lavender-top) · Serum separator (gold/red-top, SST)
Method / principle
Competitive/sandwich immunoassay or LC-MS/MS
Reagent / substrate
Anti-peptide antibody; or isotope-labeled internal standard (MS)
Platform
Immunoassay / LC-MS/MS
Turnaround · availability
Send-out / research · Research-grade
Literature evidence(1)
- C-terminal fragment of agrin (CAF) levels predict acute kidney injury after acute myocardial infarction.BMC nephrology · 2017 · PMID 28646861 · doi